-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Metastatic Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NBTXR-3 in Metastatic Liver Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Metastatic Liver Cancer Drug Details: NBTXR-3 is under development...
-
Product Insights
Oropharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Oropharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Oropharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hypopharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypopharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Hypopharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Laryngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Laryngeal Cancer - Drugs In Development, 2023’, provides an overview of the Laryngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Laryngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Marginal Zone B-cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Marginal Zone B-cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marginal Zone B-cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Pancreatic Ductal Adenocarcinoma Drug Details: NBTXR-3 is under development for the treatment of head...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PIPE-307 in Multiple Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PIPE-307 in Multiple Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PIPE-307 in Multiple Sclerosis Drug Details:PIPE-307 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SIR-2446 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SIR-2446 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SIR-2446 in Alzheimer's Disease Drug Details:SIR-2446 is under development for the treatment of...